The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).
Dirk Arnold
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Ullrich Graeven
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Christian A. Lerchenmuller
No relevant relationships to disclose
Brigitta Killing
No relevant relationships to disclose
Reinhard Depenbusch
No relevant relationships to disclose
Claus-Christoph Steffens
Consultant or Advisory Role - Roche
Honoraria - Roche
Salah-Eddin Al-Batran
No relevant relationships to disclose
Thoralf Lange
No relevant relationships to disclose
Georg Dietrich
No relevant relationships to disclose
Jan Stoehlmacher
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrea Tannapfel
No relevant relationships to disclose
Hans-Joachim Schmoll
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Anke Reinacher-Schick
Consultant or Advisory Role - Roche
Honoraria - Roche
Susanna Hegewisch-Becker
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche